Published in Retina

Putting a Laser Focus on Choosing the Right Equipment for Your Practice

This is editorially independent content supported by advertising from Norlase
4 min read

Sit down with Drs. Rishi Singh and Louis Cai as they discuss how to prioritize equipment purchases when opening a solo retina practice.

In this Evidence Based Retina episode, Rishi Singh, MD, FASRS, sits down with Louis Cai, MD, founder of Cai Retina in Sunnyvale, California, to discuss the equipment decisions behind opening a solo retina practice.
Dr. Cai, who opened his doors at the start of this month, explains how he prioritized diagnostic and laser equipment for patient care while sourcing lower-impact items secondhand to control startup costs.

Selecting a laser device for PRP fast facts

  • Diabetic retinopathy is a leading cause of vision loss among working-age adults, and panretinal photocoagulation (PRP) delivered via a laser indirect ophthalmoscope (LIO) remains a mainstay treatment—LIOs are generally favored over slit-lamp delivery because they accommodate the scleral depression and globe manipulation that far-peripheral pathology requires.1,2
  • New retina practices commonly prioritize optical coherence tomography (OCT) imaging and treatment lasers as day-one purchases since they directly affect diagnostic accuracy and outcomes, reserving secondhand or discounted buying for lower-impact items such as waiting room furnishings.
  • Peer-reviewed, within-patient comparisons show pattern-scanning PRP delivers visual field and visual acuity outcomes comparable to conventional single-spot laser, with less patient discomfort and meaningfully shorter treatment sessions—the subject of this issue's deep dive.2,3

A deeper dive into pattern-scanning PRP

Pattern-scanning platforms such as PASCAL deliver arrays of 4 to 56 burns in under one second using 10- to 30-millisecond pulses, versus the 100- to 200-millisecond, single-spot exposures of conventional laser—confining thermal spread to smaller, more uniform lesions with less collateral damage to the inner retina.2 For high-volume PRP, that translates directly into time savings.

A PRP that might have taken you 15 to 20 minutes can get down to five minutes because all of a sudden you're thinking not as single shots at a time, you're thinking about grids at a time.

A 2022 randomized, single-blind trial compared conventional and pattern-scanning PRP within the same patients—one eye received each—and found at 1 month:3
  • Pattern standard deviation (visual field variability) rose significantly in both groups, with no significant difference between them.
  • Mean deviation declined significantly only in conventional-laser eyes, though the between-group difference wasn't significant.
  • Best-corrected visual acuity change didn't differ significantly between laser types.
  • Pattern PRP caused a smaller overall reduction in visual field sensitivity.
Tolerability findings point the same direction: a systematic review of 13 randomized controlled trials and four controlled trials (1,961 eyes) found multispot laser scored roughly 2.7 points lower on a visual analog pain scale than single-spot laser, corresponding to about 40% fewer patients requiring peri-procedural analgesia.2

Choosing the right laser for your practice

New solo practices must balance patient volume against overhead, session length, and patient tolerance. That calculus shaped Dr. Cai's decision to pay a premium for a pattern-capable laser over a standard single-shot unit.
For the laser itself, Dr. Cai weighed affordability against features rather than defaulting to whatever he'd trained on. He'd used pattern lasers in fellowship and at prior clinics, but wanted a device that also matched a solo-practice workflow: portable, space-efficient, and built around a modern viewing system.
That combination led him to a newer-generation pattern LIO from Norlase, the LYNX, which integrates the laser and pattern module into a wearable, battery-powered headset rather than a separate console.4

Norlase has the most modern viewing system, and it's readily portable. Having the pattern feature makes it the only one of its kind, and I had to splurge.

A closer look at the Norlase LYNX

  • LYNX received FDA 510(k) clearance and CE Mark in January 2025 as the world's first and only pattern-scanning LIO, integrating the laser and pattern module directly into a wearable, battery-powered headset—eliminating the external console and cabling conventional pattern-scanning platforms require.4,5
  • The device offers grid patterns up to 5×5, one to three concentric circles, and adjustable arc patterns, controlled wirelessly via a tablet with multilingual voice control; its footswitch-integrated battery delivers more than a full day of use on a single charge.5,6
  • Unlike conventional pattern lasers, which fix the position of the laser beam and eyelids during treatment, LYNX allows unrestricted movement of the lens, eye, and laser beam.7

Test before you buy

Dr. Cai's advice to colleagues shopping for any piece of equipment, laser included, is to insist on hands-on time before purchasing.
After reaching out to a company representative, he arranged to have a demo unit shipped to his office—the first shipment he ever received there—and used it on a handful of straightforward patients before deciding. A demo lets a surgeon confirm the optics and workflow fit under real clinical conditions, not just a showroom demonstration.

If you haven't used a new laser...it's hard to trust a new laser, and the first thing I would ask for is just a demo.

In closing

For a solo practice built on volume and reputation, laser choice isn't a cosmetic upgrade. The evidence shows pattern-scanning PRP matches conventional single-spot laser on efficacy while meaningfully cutting treatment time and discomfort.
For anyone building a practice from the ground up, prioritizing devices that influence outcomes—while sourcing lower-stakes purchases secondhand—is a reasonable framework for controlling costs without compromising care.
  1. Ahmad I, Mahsood YJ. Ultra-widefield fluorescein angiography-based targeted retinal photocoagulation versus panretinal photocoagulation in proliferative diabetic retinopathy: a randomized controlled trial. Pak J Med Sci. 2025;41(10):2809-2814. doi:10.12669/pjms.41.10.12535
  2. Xie X, Munir L, Paulus YM. Retinal laser therapy mechanisms, innovations, and clinical applications. Photonics. 2025;12(11):1043. doi:10.3390/photonics12111043
  3. Hassanpoor N, Ahoor M, Latifi A, Niyousha M. Conventional and pattern scanning pan-retinal photocoagulation laser in diabetic patients' visual field. J Lasers Med Sci. 2022;13:e40. doi:10.34172/jlms.2022.40
  4. Koennecke G. Norlase receives FDA 510(k) clearance and CE mark for LYNX pattern scanning laser indirect ophthalmoscope. Ophthalmology Times. January 27, 2025. Accessed August 25, 2026. https://www.ophthalmologytimes.com/view/norlase-receives-fda-510-k-clearance-and-ce-mark-for-lynx-pattern-scanning-laser-indirect-opthalmoscope.
  5. LYNX laser indirect ophthalmoscope with pattern scanning. Norlase. Accessed August 25, 2026. https://norlase.com/lynx/.
  6. Appold K. LYNX LIO offers pattern delivery and portability. Ophthalmology Management. May 2025. Accessed August 25, 2026. https://www.ophthalmologymanagement.com/issues/2025/may/spotlight-on-technology-and-technique/.
  7. Charters L. Initial impressions with pattern laser indirect ophthalmoscope in first 10 patients. Ophthalmology Times. Accessed August 25, 2026. https://www.ophthalmologytimes.com/view/initial-impressions-with-pattern-laser-indirect-ophthalmoscope-in-first-10-patients.
Rishi P. Singh, MD, FASRS
About Rishi P. Singh, MD, FASRS

Rishi P. Singh, MD, FASRS, is the Chair of the Department of Ophthalmology at Mass General Brigham, overseeing ophthalmology across Massachusetts Eye and Ear, Massachusetts General Hospital, Brigham and Women’s Hospital, and affiliated sites. He is also a Professor of Ophthalmology at Harvard Medical School.

Previously, Dr. Singh served as Vice President and Chief Medical Officer at Cleveland Clinic Martin Health in Stuart, Florida, and as a staff surgeon at the Cleveland Clinic, where he was also Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio. He received both his undergraduate degree in medical science and his medical degree from Boston University, completing his internship at Tufts University. Dr. Singh went on to complete his ophthalmology residency at the Massachusetts Eye and Ear Infirmary/Harvard Medical School and a medical and surgical vitreoretinal fellowship at the Cole Eye Institute at the Cleveland Clinic.

Dr. Singh specializes in the management of complex retinal diseases, including diabetic retinopathy, retinal vein occlusions, retinal detachment, and age-related macular degeneration. He has authored over 300 peer-reviewed publications, books, and book chapters and serves as Principal Investigator for numerous national and international clinical trials aimed at improving outcomes for patients with retinal diseases.

He is the founder and past president of the Retina World Congress, chairs some of the largest continuing medical education meetings in retina, and serves on editorial boards and review panels for major ophthalmology journals. His leadership has extended into digital innovation, having helped lead enterprise-wide implementation of clinical technologies including Epic modules, digital informed consent, and patient-facing kiosks.

Dr. Singh has received multiple accolades for his contributions to ophthalmic research and innovation, including the Alpha Omega Alpha Research Award, the American Society of Retina Specialists Young Investigator Award, and the J. Donald Gass Beacon of Sight Award. He also leads The Center for Ophthalmic Bioinformatics, a research initiative focused on leveraging big data and artificial intelligence to advance understanding and treatment of retinal disease.

Rishi P. Singh, MD, FASRS
Louis Cai, MD
About Louis Cai, MD

Louis Cai, MD, is a board-certified ophthalmologist with specialty training in vitreoretinal surgery. He graduated summa cum laude from a combined BS/MD program at the University of Miami.

He completed his ophthalmology residency at the esteemed Wills Eye Hospital in Philadelphia. He received specialty training in vitreo­retinal surgery at Bascom Palmer Institute in Miami.

He treats medical and surgical retinal conditions including retinal tears, retinal detachments, age related macular degeneration, secondary lens placement, and diabetic retinopathy. He has coauthored over 30 papers and presentations, and has a particular interest in the intersection of artificial intelligence and medicine.

He is the producer and cohost of Straight From the Cutters Mouth, a Retina Podcast (retinapodcast.com), the longest running podcast for vitreoretinal surgeons, and is an active member of the American Academy of Ophthalmology, American Society of Retina Specialists, and the Vit Buckle Society.

Originally from Florida, Dr. Cai is fluent in English and proficient in Spanish and Mandarin Chinese. Outside of clinic, he is the cofounder of Cosign AI, a digital health startup, and enjoys spending time outdoors with his wife and two kids.

Louis Cai, MD
💙 Evidence Based Retina
Astellas
Regeneron
Bausch + Lomb Xipere
EyePoint Pharmaceuticals
Apellis Pharmaceuticals
Norlase